Skip to main content
. 2022 Apr 7;14(4):813. doi: 10.3390/pharmaceutics14040813

Figure 8.

Figure 8

CBSA serves as a siRNA delivery vector for treating lung disease [104]. (A) Representative ex vivo fluorescence image of major organs from mice sacrificed at 15 min or 2 h after i.v. injection of Cy3-labeled siRNA alone or complexed with CBSA or Lipofectamine 2000. (B) RT-PCR analysis of the silencing efficiency of siRNA in major organs. (C) Representative images of lung tissue section.